"Pfizer's Sickle Cell Setbacks, Viking Therapeutics' Weight Loss Success, and the Rise of AI in Healthcare"
Update: 2024-03-27
Description
"AI in Life Sciences" is a podcast that dives into the latest happenings and innovations in the life sciences industry. In today's episode, we discuss Pfizer's decision to end one of its clinical trials focused on a sickle cell treatment, and how it would affect their plans for the drug's approval. We'll also delve into new obesity data from Viking Therapeutics, and how their dual agonist, VK2735, has shown promising results in weight reduction.
The importance of high-quality data in AI projects cannot be undervalued, and we take a closer look at how 'data health' is pivotal to the success of AI innovations. Furthermore, we explore a groundbreaking gene therapy by Nanoscope Therapeutics, that is offering hope to millions suffering from retinal diseases.
As the Supreme Court deliberates on the in-person dispensing requirement for mifepristone, we consider its potential impact on the biopharma industry and reproductive rights. And lastly, we shed light on the rise of AI-integrated medical devices that are redefining the healthcare sector. Tune in to get the latest updates from the world of life sciences.
The importance of high-quality data in AI projects cannot be undervalued, and we take a closer look at how 'data health' is pivotal to the success of AI innovations. Furthermore, we explore a groundbreaking gene therapy by Nanoscope Therapeutics, that is offering hope to millions suffering from retinal diseases.
As the Supreme Court deliberates on the in-person dispensing requirement for mifepristone, we consider its potential impact on the biopharma industry and reproductive rights. And lastly, we shed light on the rise of AI-integrated medical devices that are redefining the healthcare sector. Tune in to get the latest updates from the world of life sciences.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
